These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38698816)

  • 1. Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia's perspective.
    Alakeel YS; Rampakakis E; AlRumaih A; AlRuwaisan R; Abushal M; AlDalaan AM; Idrees MM; Alanazi ZD; AlKoait H; Muaadi A; AlAfra MAM; AlShaya SA; AlHomida S
    Front Pharmacol; 2024; 15():1376009. PubMed ID: 38698816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence, Drugs with Narrow Therapeutic Index and The Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution.
    Gozzo L; Caraci F; Drago F
    Healthcare (Basel); 2022 Jul; 10(8):. PubMed ID: 35893214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.
    Karalis V; Macheras P; Bialer M
    CNS Drugs; 2014 Jan; 28(1):69-77. PubMed ID: 24092569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.
    Di Paolo A; Arrigoni E
    Drugs; 2018 Mar; 78(4):399-410. PubMed ID: 29464665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?
    Dupont AG; Heller F
    Acta Clin Belg; 2009; 64(5):406-14. PubMed ID: 19999388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bioequivalence and generics of index drugs with narrow therapeutic margins].
    Le Corre P
    Presse Med; 2010 Feb; 39(2):169-76. PubMed ID: 19932591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe.
    Odi R; Franco V; Perucca E; Bialer M
    Epilepsia; 2021 Feb; 62(2):285-302. PubMed ID: 33426641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
    Borgheini G
    Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical and regulatory considerations in assessments of interchangeability of biological drug products.
    Tóthfalusi L; Endrényi L; Chow SC
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S5-11. PubMed ID: 24832831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brand and generic medications: are they interchangeable?
    Al-Jazairi AS; Bhareth S; Eqtefan IS; Al-Suwayeh SA
    Ann Saudi Med; 2008; 28(1):33-41. PubMed ID: 18299655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
    Bialer M; Midha KK
    Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.
    Meredith PA
    Curr Med Res Opin; 2009 Sep; 25(9):2179-89. PubMed ID: 19601710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy?
    Holtkamp M; Theodore WH
    Epilepsia; 2018 Jul; 59(7):1273-1281. PubMed ID: 29894004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
    Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
    Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence and other unresolved issues in generic drug substitution.
    Meredith P
    Clin Ther; 2003 Nov; 25(11):2875-90. PubMed ID: 14693311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.